Adherium (ASX:ADR) announced an acceleration in its commercial strategy, driven by the strong performance of its Hailie Smartinhaler platform.
In a quarter-to-date sales update, the company highlighted a substantial 51% increase in remote patient monitoring revenue, climbing from $68,000 in December 2025 to $103,000 in February 2026.
The combined revenue for January and February has already reached $198,000, surpassing the entire previous quarter’s total with one month still remaining.
Cumulative RPM device shipments rose by 43%, reaching 3,071 units, while patient activations saw a 53% jump to 2,183.
Adherium credits this trajectory to its dedicated Care Team and a streamlined billing environment.
The introduction of new CPT reimbursement codes on Jan. 1 has lowered billing thresholds, allowing for earlier and more efficient revenue collection—a move the company describes as a significant "tailwind" for the 2026 calendar year.
Furthermore, Adherium has expanded its scalability through strategic partnerships, including a collaboration with Allergy Partners.
The alliances provide the company access to approximately 48,000 insurance-verified asthma patients with compatible devices.
At the time of reporting, Adherium's share price was $0.0020.